AEGiS-ATDN: Tipranavir and Atazanavir

Important note: Information in this article was accurate in 2003. The state of the art may have changed since the publication date.

Tipranavir and Atazanavir

Information Bulletin #17 - February 2003

Atazanavir, a protease inhibitor, is available on an Expanded Access Program (EAP) that doctors can enroll in their patients in by filling out a form and collecting data on how participants are doing. This drug is now no longer known as Zrivada, nor is it called TAZ. The Bristol-Myers Squibb Company has already enrolled around 2,000 people in the program. Almost anyone who might want to take the drug is eligible if they can't tolerate any existing drug combinations for one of many reasons, or they are having blood lipid problems like elevated triglycerides. For more info on the program physicians may call toll free 1-877-726-7327. People taking Kaletra should only take atazanavir once a day, instead of twice a day. Many other drug interactions are still unknown at this point.

Tipranavir,according to Boehringer Ingelheim, is available in the largest clinical trials ever undertaken in patients previously treated with three classes of antiretrovirals. This is the first non-peptidic protease inhibitor developed. The RESIST clinical trial program consists of several Phase III studies.The dose for tipranavir that will be studied in the Phase III clinical program is 500 mg of tipranavir taken with 200 mg of ritonavir (to boost tipranavir drug levels in the body) twice daily. Other studies of tipranavir will be conducted in treatment-na ve adults and children aged 2-18. A list of U.S. sites is at http://us.boehringer-ingelheim.com or http://www.clinicaltrials.gov. ACRIA and Pollari Medical group are recruiting in New York City. Go to http://www.atdn.org/tip.html for full press release.

030210
TR030207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .